Keywords
Chemotherapy
Stage IIIb–IV
Non-small cell lung cancer
Submitted : 2024-07-10
Accepted : 2024-07-25
Published : 2024-08-09
Abstract
Objective: To analyze the therapeutic effect of tislelizumab combined with chemotherapy in patients with stage IIIb–IV non-small cell lung cancer (NSCLC). Methods: A total of 50 patients with stage IIIb–IV NSCLC admitted between January 2022 and January 2024 were randomly divided into two groups using a random number table. The observation group included 25 cases treated with tislelizumab combined with chemotherapy, while the reference group included 25 cases treated with conventional chemotherapy. The clinical control rate, adverse reaction rate, tumor markers, immune function indicators, and quality of life scores were compared between the two groups. Results: The observation group had a higher clinical control rate and a lower adverse reaction rate compared to the reference group (P < 0.05). Before treatment, there were no significant differences in tumor markers, immune function indicators, and quality of life scores between the two groups (P > 0.05). Three months after treatment, the tumor marker levels in the observation group were lower than those in the reference group. Except for CD8+, all immune function indicators in the observation group were higher than those in the reference group, and the quality-of-life scores in the observation group were higher than those in the reference group (P < 0.05). Conclusion: Implementing tislelizumab combined with chemotherapy in patients with stage IIIb–IV NSCLC can improve the clinical control rate, reduce the adverse reaction rate, lower tumor marker levels, protect immune function, and improve quality of life.
References
Li X, Zhang Y, Yao S, et al., 2024, Clinical Study on the Treatment of Stage IIIb–IV Non-Small Cell Lung Cancer with Tislelizumab Combined with Chemotherapy. Chinese Journal of Clinical Pharmacology, 40(3): 335–339.
Liu S, Liu Q, Pang Q, et al., 2024, The Effect of Tislelizumab Combined with Chemotherapy in the Treatment of Stage IIIb–IV Non-Small Cell Lung Cancer. Journal of Practical Hospital Clinical, 21(3): 112–116.
Chen X, Liu T, Yang M, et al., 2022, Efficacy of Different Immune Checkpoint Inhibitors Combined with Chemotherapy in the Treatment of Non-Small Cell Lung Cancer and Their Impact on Tumor Marker Levels. Chinese Clinical and Rehabilitation Oncology, 29(7): 774–778.
Zhao H, Guo C, Zhao W, 2024, Clinical Study of Tislelizumab Combined with Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer. System Medicine, 9(7): 175–178.
Lu S, Yu X, Hu Y, et al., 2023, Characteristics of Tumor Response to First-Line Treatment with Tislelizumab Combined with Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. Chinese Journal of Oncology, 45(4): 358–367.
Chen F, Liang H, Cheng G, et al., 2023, Study on the Short-Term Efficacy and Safety of Tislelizumab Combined with Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. Journal of Clinical and Experimental Medicine, 22(6): 583–587.
Fu H, Nan Y, Li C, et al., 2023, The Effect of Albumin-Bound Paclitaxel and Carboplatin Combined with Tislelizumab in the Treatment of Advanced Non-Small Cell Lung Cancer. Northwest Pharmaceutical Journal, 38(4): 164–168.
Zhang J, Lu Z, Zhou X, 2022, Efficacy and Impact on Immune Function of Tislelizumab Combined with GP Chemotherapy Regimen in the Treatment of Advanced NSCLC. Chinese Journal of Health Care Medicine, 24(3): 252–254.
Cheng Y, Liu L, 2023, Predictive Value of NLR and MLR in the Efficacy of Tislelizumab Combined with TP Regimen for NSCLC. Anhui Medical Journal, 44(12): 1472–1477.
Chen Z, 2023, Clinical Study of Tislelizumab Combined with Gemcitabine and Cisplatin in the Treatment of Advanced Lung Squamous Carcinoma. Chinese Journal of Clinical Pharmacology, 39(16): 2306–2310.
Ren G, Wu X, Song X, et al., 2023, Analysis of Diagnosis and Treatment Strategies and Pharmaceutical Care for Tislelizumab-Induced Immune-Related Pneumonia. Chinese Journal of Hospital Pharmacy, 43(11): 1291–1295.
Wang H, Liu Y, Li A, et al., 2024, The Effects of Tislelizumab Injection Combined with Albumin-Bound Paclitaxel and Carboplatin on Intestinal Flora, SII, and PNI in Patients with Advanced NSCLC. Progress in Modern Biomedicine, 24(2): 338–342.